meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 2nd line (L2)
1
sarcomas
thyroid cancer
urothelial cancer (UC) - bladder cancer (BC)
<span style="margin-left: 0em;">immune chekpoint inhibitors</span>
<span style="margin-left: 1em;">anti-PD-(L)1</span>
<span style="margin-left: 2em;">nivolumab based treatment</span>
<span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">mTOR inhibitors</span>
<span style="margin-left: 1em;">everolimus <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (1)
progression or deaths (PFS) (1)
objective responses (ORR) (1)
deaths (OS) (extension) (1)
DOR (1)
objective responses (ORR) (extension) (1)
DOR (extension) (1)
TRAE (any grade) (1)
TRAE (grade 3-4) (1)
TRAE leading to death (grade 5) (1)
TRAE leading to discontinuation (any grade) (1)
Pruritus TRAE (grade 3-4) (1)
Rash TRAE (grade 3-4) (1)
Diarrhoea TRAE (grade 3-4) (1)
Fatigue TRAE (grade 3-4) (1)
Nausea TRAE (grade 3-4) (1)
Anaemia TRAE (grade 3-4) (1)
Decreased appetite TRAE (grade 3-4) (1)
Dyspnoea TRAE (grade 3-4) (1)
Pneumonitis TRAE (grade 3-4) (1)
Cough TRAE (grade 3-4) (1)
Peripheral oedema TRAE (grade 3-4) (1)
Mucosal inflammation TRAE (grade 3-4) (1)
Dysgeusia TRAE (grade 3-4) (1)
Stomatitis TRAE (grade 3-4) (1)
Epistaxis TRAE (grade 3-4) (1)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for deaths (OS)
1
CheckMate 025, 2015
everolimus
nivolumab alone
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
everolimus
nivolumab alone
everolimus
---
NA
nivolumab alone
NA
---
pathologies: 80 - treatments: 360,719,721,720
result logic
×
Study list
